Thank you, Reade and good morning everyone. Before I discuss our results, I would like to introduce our new Head of Investor Relations, Tamara Gonzalez. Tamara is an experienced Investor Relations professional, well versed in the consumer sector having spent time on the sell side covering broadline retail companies after starting her career in Investor Relations at The Home Depot. We are excited to have her on board, as we further our Investor Relations efforts. Turning now to our results. As Reade said, we are pleased to have delivered fourth quarter and full year results that came in ahead of our expectations. Our strong year-end results were driven by crisp execution of our strategic initiatives and disciplined expense management, driving both top line improvement in our growth brands and better-than-expected adjusted operating income. Throughout the fiscal year, we made solid progress in improving exam capacity and mitigating the impact of dark and dense stores on our results. For the year, on average, dark stores represented a low single-digit percentage of our America's Best fleet, which is in line with our historical norm and an improvement from the peak mid-single-digit percentage we saw in 2022. Dim stores on average for the year represented a high single-digit percentage of the America's Best fleet, reflecting a trend that is still higher than our historical norm, but an improvement compared to the prior year. As Reade noted, store openings remain an important part of our growth plan and doctor availability, as well as remote capabilities are key considerations in our expansion plans as we select locations for new store openings. Now, moving on to our fourth quarter results in more detail. For the fourth quarter, net revenue increased 8% compared to the prior year, driven by adjusted comparable store sales growth of 5.7% and growth from new store sales. Adjusted comparable store sales were driven by an increase in customer transactions and to a lesser extent higher average ticket. The timing of unearned revenue benefited revenue in the period by 20 basis points. We opened 16 new America's Best and one Eyeglass World store in the fourth quarter. Unit growth in our America's Best and Eyeglass World brands increased 4.4% on a combined basis over the total store base last year and we ended the quarter with 1,413 stores. As a percentage of net revenue costs applicable to revenue increased approximately 140 basis points compared with the prior year quarter, driven primarily by higher optometrist-related costs and a lower service revenue including warranty revenue as well as other mix and margin effects. These cost increases were offset by ongoing strength in exam revenue as well as a decrease in freight expense. For the quarter, the net impact from deleverage of optometrist-related costs and the increase in exam revenue was approximately 90 basis points, which is higher than previous quarters in the year due to timing of benefit-related accruals. Adjusted SG&A expense as a percentage of revenue decreased 260 basis points compared with the fourth quarter of 2022. The decrease in adjusted SG&A as a percentage of net revenue was primarily driven by lower advertising, legal and professional expenses, and reflects disciplined expense management we have taken across the organization. Depreciation and amortization expense was $24.1 million compared to $24.7 million in the prior year period and was slightly better than our expectations, primarily due to the intangible asset impairment recorded as a result of the termination of our Walmart partnership. Adjusted operating income was $0.3 million compared to an adjusted operating loss of $6.8 million in the prior year period. Adjusted operating margin increased 150 basis points to 0.1% compared to the prior year period due primarily to factors previously discussed. Net interest expense was $3.9 million compared to $2.6 million in the prior year period. The year-over-year interest increase was driven primarily by an increase of $3.1 million of non-cash mark-to-market charges, which were offset by an increase in interest income of $1 million and a decrease in interest expense of $0.8 million compared to the prior year period. As a reminder our interest guidance excludes non-cash mark-to-market and deferred financing costs which totaled $4.3 million for the period. Excluding these costs, interest was a benefit of $0.4 million. Our effective tax rate in the fourth quarter was 10.1%, primarily due to increases in unfavorable book-to-tax differences, which offset the tax benefit of the pre-tax book loss in the period. Adjusted diluted EPS was negative $0.02 per share in the fourth quarter compared to negative $0.08 per share in the prior year period. Turning to our financial results for fiscal 2023 compared to the prior year period. Net revenue increased 6% driven by new stores and adjusted comparable store sales growth of 2.9%, the timing of unearned revenue positively impacted net revenue by 20 basis points. Adjusted operating margin declined 100 basis points compared with the prior year period, driven primarily by the expected deleverage of optometrist-related costs and the normalization of our incentive compensation program. For the year, adjusted diluted earnings per share were $0.64 compared to $0.65 in fiscal 2022. Please note, our adjusted results for the fourth quarter and full year exclude the impacts associated with one-time charges related to the termination of our Walmart partnership and related wind down of AC Lens operations, cost savings initiatives, charges related to our ERP rollout and other non-recurring items that are detailed in the reconciliation tables found in our press release. We are on track to substantially complete the first phase of our ERP project by the end of fiscal 2024. During 2023, we incurred approximately $2.5 million of expenses related to the project, of which approximately $2 million was capitalized. We continue to expect to incur approximately $11 million to $13 million in one-time expenses related to the first phase of the project, inclusive of the 2023 expenses. Turning next to our balance sheet. We ended the year with a cash balance of approximately $150 million and total liquidity of $444 million, including available capacity from our revolving credit facility. As of December 30, our total debt outstanding was $465 million and for the trailing 12 months, we ended the year with a net debt to adjusted EBITDA of 1.9 times. In 2023, we generated operating cash flow of $173 million and invested $116 million in capital expenditures, primarily driven by investments in new stores, our labs, distribution center, doctor equipment and in-store lab equipment. As we announced in November, we repurchased $100 million of our convertible senior notes for an aggregate cash repurchase price, inclusive of premium paid of $99.25 million. We continue to maintain a strong balance sheet and healthy cash flow to support our growth and capital allocation priorities. In 2024, our first priority with respect to capital allocation will continue to be the investment in our growth through new store openings and technology investments as we continue to digitize our stores in corporate office. Our second priority will be our focus on our debt structure, given the pending May 2025 maturity of the convertible notes. As we demonstrated, with the repurchase in November, we plan to take fiscally responsible actions with our outstanding balance and are monitoring the market for future opportunistic actions and other potential strategies. Our third priority is returning excess cash to shareholders. While we do not expect to repurchase shares in the near term given our other stated priorities for 2024, we are pleased to announce a new repurchase authorization of $50 million in place through January 3, 2026, given our original repurchase authorization expired on December 30, 2023. We continue to evaluate opportunities to repurchase shares based on available investment opportunities, our financial position, and market conditions. Moving now to the discussion of our 2024 outlook. For our 2024 fiscal year, we currently expect net revenue between $1.965 billion and $2.005 billion supported by adjusted comparable store sales growth of 2% to 4% and new store sales based on our expectation to open between 65 and 70 new stores this year. With respect to profitability for 2024, we expect adjusted operating income between $61 million and $76 million. This includes the range for depreciation and amortization of $95 million to $100 million. We expect adjusted diluted EPS to be between $0.50 per share and $0.65 per share, which assumes approximately 79 million weighted average diluted shares outstanding. Our guidance range includes, the expected revenue and profitability from Walmart and AC Lens operations through their respective contract terms. As laid out on slide 15 of our earnings presentation, we expect legacy segment revenue of approximately $16 million and adjusted operating income of $0.5 million in the first quarter. And AC Lens is expected to deliver approximately $129 million of revenue and $2 million of adjusted operating income in the first half of the year split evenly across first and second quarter. In addition, our outlook for fiscal 2024 assumes a range of scenarios with respect to consumer sentiment ongoing success with our America's Best brand and performance improvement in Eyeglass World. As Reade noted the year started softer than expected but we have seen sequential improvement as the quarter has progressed. While it is not our practice to provide quarterly guidance, given where we are in the quarter we felt it appropriate to provide some direction for modeling purposes. We expect first quarter adjusted comparable store sales to be flat to slightly negative compared to the prior year. This expectation incorporates a 40 to 50 basis point drag from Walmart performance. The high end of our full year guidance assumes further strengthening in trends as the year progresses supported by continued strong performance in America's Best and improved performance in Eyeglass World, as well as improved consumer backdrop. The low end of our guidance assumes a weaker consumer environment impacting demand trends and less success in improving Eyeglass World's performance through the operational changes Reade discussed. As we discussed on our last call, the profit gap created by the Walmart partnership termination would be addressed through non-headline pricing and expense actions which were implemented before the end of fiscal 2023, allowing us to realize the full year benefit in 2024, which more than offset this headwind. The pricing actions focused on stand-alone exams and targeted product offerings which are expected to benefit 2024 by approximately $15 million. In addition to the pricing actions, we also streamlined corporate overhead and third-party spend in the fourth quarter of 2023, which we expect will result in approximately $10 million of annualized cost savings in 2024. At the midpoint of our guidance range, we expect to deliver an adjusted operating income margin in line with fiscal 2023, which came in ahead of expectations due to operational improvement in America's Best and disciplined expense management. We also expect gross margin expansion of approximately 200 basis points for the year. This assumes benefits from the pricing actions, margin expansion as we exit the lower margin Walmart and AC Lens businesses and improved productivity. In addition, we expect adjusted SG&A to deleverage approximately 150 basis points, primarily driven by the year-over-year decline in revenue given the termination of Walmart business. This expectation also considers the $10 million of annualized cost savings as well as increased levels of annual operating expense, related to cloud amortization and ongoing investments in our growth. We expect marketing spend dollars to be below 2023. But as Reade noted, we will be shifting marketing dollars to focus on driving improved Eyeglass World performance, while continuing to leverage the strong national presence that America's Best holds. Looking further ahead, we believe we are well positioned to achieve our mid-single-digit adjusted operating margin target in 2025. However, the composition of how we expect to get there has evolved. Remote is now more fully embedded in our normal course of business and as we have discussed is an important tool in delivering improved results within the America's Best brand, as reflected in our 2023 performance. We expect this capability to continue to be a healthy contributor to our overall financial results, going forward and its benefit is incorporated in our 2024 guidance along with our updated plans for deployment which Reade reviewed. In addition to remote, our 2025 margin target also included expectations related to returning to mid-single-digit adjusted comp performance, driven by expanding exam capacity and improving consumer sentiment. We have been and continue to be acutely focused on the factors of comp that we can control with respect to exam capacity and pricing and are continuing to monitor the evolving trends within the optical purchase cycle that Reade discussed. Given these current views on remote and the progress we are making in driving improved top line results, we now expect future margin expansions to come primarily from improved productivity, gross margin expansion and expense leverage across the company through 2024 and into 2025. As illustrated on Slide 17, with the strong progress made in 2023, and assuming we deliver at least the midpoint of our 2024 expectations for adjusted operating margin we will be well positioned to achieve mid-single-digit adjusted operating margin in 2025. As we have always said, our 2025 objective is not our end goal. And we will continue to drive further margin improvement going forward. I am proud of our team's dedication and focus on driving our initiatives to-date, and believe we remain well positioned to deliver our objectives including driving value for our shareholders. Thank you for your time today. I will now turn the call over to Reade, for closing remarks before we open the call for questions. Reade?